Filing Details
- Accession Number:
- 0001104659-19-036491
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-06-19 21:03:13
- Reporting Period:
- 2019-06-17
- Accepted Time:
- 2019-06-19 21:03:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1481512 | Ra Pharmaceuticals Inc. | RARX | Pharmaceutical Preparations (2834) | 262908274 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1688195 | Ramin Farzaneh-Far | C/O Ra Pharmaceuticals, Inc. 87 Cambridgepark Drive Cambridge MA 02140 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-06-17 | 1,389 | $5.60 | 8,521 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-06-17 | 9,206 | $5.60 | 17,727 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-06-17 | 3,411 | $21.41 | 14,316 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-06-17 | 7,184 | $22.04 | 7,132 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to buy) | Disposition | 2019-06-17 | 1,389 | $0.00 | 1,389 | $5.60 |
| Common Stock | Stock Options (Right to buy) | Disposition | 2019-06-17 | 9,206 | $0.00 | 9,206 | $5.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 23,611 | 2026-08-16 | No | 4 | M | Direct | |
| 156,508 | 2026-08-16 | No | 4 | M | Direct |
Footnotes
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $20.91 to $21.905. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $21.92 to $22.09. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- These stock options vest over a four (4) year period in 48 equal monthly installments at the end of each month following August 16, 2016.
- These stock options vest a four (4) year period with the first twenty five percent (25%) of such shares vesting on the first anniversary of July 11, 2016, and the remaining shares vesting in equal monthly installments at the end of each month following the first anniversary of July 11, 2016 over the following thirty six (36) months, subject to the terms set forth in the applicable equity agreement.
Billionaire Hedge Funds
